Worried about how mobile you are? Scared of losing your balance and falling? There’s a simple clinical test that’s used by ...

GoodRx is expanding access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron) Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx GoodRx is ...

Kroger said it is now stocking Eli Lilly's injection pen version of the weight-loss drug Zepbound, and will allow self-pay customers to use Lilly's savings card at its retail pharmacies. The ...

Kroger is now offering Zepbound KwikPen, a multidose version of Eli Lilly’s GLP-1 weight loss drug, at participating retail pharmacy locations. The rollout marks the first time self-pay patients may ...

Amazon's pharmacy arm has expanded access to the Eli Lilly's new Zepbound KwikPen injectable treatment for weight management. The multi-dose treatment is designed to deliver a full month of medication ...

Amazon Pharmacy now offers customers transparent cash-pay pricing starting at $299 per month for the 2.5 mg KwikPen starter dose and convenient, fast home delivery. Amazon Pharmacy (NASDAQ: AMZN), a ...

A date has been set for the rollout of the redesigned Mounjaro KwikPens in the UK, killing off the controversial 'golden dose' once and for all. The change means some Mounjaro users will soon receive ...

GoodRx to collaborate with Eli Lilly to expand employer-sponsored access to Zepbound® KwikPen®, an FDA-approved dual GIP and GLP-1 obesity treatment Through GoodRx Employer Direct, self-insured ...

Credit: Lilly. The 4-dose KwikPen device supports weight reduction in patients with obesity or overweight with weight-related conditions. The device is for single-patient use only and should never be ...

Eli Lilly and Company (NYSE: LLY) announced on February 23, 2026, that the U.S. Food and Drug Administration has approved a label expansion for Zepbound, its blockbuster obesity drug, to include a new ...